Spots Global Cancer Trial Database for primary peritoneal carcinosarcoma

Every month we try and update this database with for primary peritoneal carcinosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	NCT03641287	Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton...	Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice	18 Years -	University of Washington
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	NCT03641287	Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton...	Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice	18 Years -	University of Washington
A Study of FRaDCs for Ovarian Cancer	NCT05920798	Fallopian Tube ... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Multi-epitope F... Pembrolizumab Pheresis	18 Years -	Mayo Clinic
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	NCT04919629	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Serous ... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Biopsy Biospecimen Col... Pegcetacoplan Pembrolizumab Questionnaire A...	18 Years -	Roswell Park Cancer Institute
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	NCT02364713	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Gemcitabine Hyd... Laboratory Biom... Oncolytic Measl... Paclitaxel Pegylated Lipos... Quality-of-Life... Topotecan Hydro...	18 Years -	Mayo Clinic
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	NCT02364713	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Gemcitabine Hyd... Laboratory Biom... Oncolytic Measl... Paclitaxel Pegylated Lipos... Quality-of-Life... Topotecan Hydro...	18 Years -	Mayo Clinic
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	NCT04919629	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Serous ... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Biopsy Biospecimen Col... Pegcetacoplan Pembrolizumab Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	NCT02020707	Cervical Adenoc... Cervical Adenos... Cervical Adenos... Cervical Carcin... Cervical Squamo... Clinical Stage ... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Und... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Femal... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Perit... Malignant Solid... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Mucinou... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Unresectable Me... Uterine Corpus ...	Bevacizumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: